MX2018013573A - Ciertos inhibidores de la proteína cinasa. - Google Patents

Ciertos inhibidores de la proteína cinasa.

Info

Publication number
MX2018013573A
MX2018013573A MX2018013573A MX2018013573A MX2018013573A MX 2018013573 A MX2018013573 A MX 2018013573A MX 2018013573 A MX2018013573 A MX 2018013573A MX 2018013573 A MX2018013573 A MX 2018013573A MX 2018013573 A MX2018013573 A MX 2018013573A
Authority
MX
Mexico
Prior art keywords
protein kinase
kinase inhibitors
certain protein
certain
inhibitors
Prior art date
Application number
MX2018013573A
Other languages
English (en)
Inventor
Yang Lijun
Li Tongshuang
Zhao Xingdong
Wang Xianlong
Liu Yanxin
Lin Min
Chen Zhifang
Wang Weibo
Chen Ling
Tan Rui
Zhou Zuwen
Sun Jing
Original Assignee
Shanghai Fochon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fochon Pharmaceutical Co Ltd filed Critical Shanghai Fochon Pharmaceutical Co Ltd
Publication of MX2018013573A publication Critical patent/MX2018013573A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se proporcionan ciertos inhibidores de CDK4/6, composiciones farmacéuticas de los mismos y métodos de uso de los mismos.
MX2018013573A 2016-05-07 2017-05-05 Ciertos inhibidores de la proteína cinasa. MX2018013573A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662333165P 2016-05-07 2016-05-07
PCT/CN2017/083162 WO2017193872A1 (en) 2016-05-07 2017-05-05 Certain protein kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2018013573A true MX2018013573A (es) 2019-08-01

Family

ID=60266275

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013573A MX2018013573A (es) 2016-05-07 2017-05-05 Ciertos inhibidores de la proteína cinasa.

Country Status (15)

Country Link
US (1) US10835535B2 (es)
EP (1) EP3452484B1 (es)
JP (1) JP6927548B2 (es)
KR (1) KR102374033B1 (es)
CN (1) CN109153686B (es)
AU (1) AU2017262155B2 (es)
BR (1) BR112018072699A2 (es)
CA (1) CA3023460A1 (es)
DK (1) DK3452484T3 (es)
ES (1) ES2954148T3 (es)
MX (1) MX2018013573A (es)
RU (1) RU2738837C2 (es)
TW (1) TWI752026B (es)
WO (1) WO2017193872A1 (es)
ZA (1) ZA201808238B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020015431A2 (pt) 2018-02-15 2020-12-08 Nuvation Bio Inc. Compostos heterocíclicos como inibidores de quinase
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
EP1019385B1 (en) 1995-09-15 2004-01-14 PHARMACIA & UPJOHN COMPANY Aminoaryl oxazolidinone n-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
US7307163B2 (en) 2004-04-19 2007-12-11 Symed Labs Limited Process for the preparation of linezolid and related compounds
US7429661B2 (en) 2004-07-20 2008-09-30 Symed Labs Limited Intermediates for linezolid and related compounds
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
EP2121641B1 (en) 2007-02-15 2014-09-24 F. Hoffmann-La Roche AG 2-aminooxazolines as taar1 ligands
KR20100105802A (ko) 2007-04-19 2010-09-29 콘서트 파마슈티컬즈, 인크. 중수소화된 모르폴리닐 화합물
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
DE102007038251A1 (de) 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
EP2209774A1 (en) 2007-10-02 2010-07-28 Concert Pharmaceuticals Inc. Pyrimidinedione derivatives
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009055006A1 (en) 2007-10-26 2009-04-30 Concert Pharmaceuticals, Inc. Deuterated darunavir
SI2215094T1 (sl) 2007-11-15 2016-05-31 Ym Biosciences Australia Pty Ltd N vsebujoče heterociklične spojine
EP2331547B1 (en) 2008-08-22 2014-07-30 Novartis AG Pyrrolopyrimidine compounds as cdk inhibitors
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
FR2988722B1 (fr) 2012-04-03 2014-05-09 Sanofi Sa Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques
ES2715462T3 (es) * 2014-05-28 2019-06-04 Shanghai Fochon Pharmaceutical Co Ltd Ciertos inhibidores proteínas quinasa
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途

Also Published As

Publication number Publication date
EP3452484A1 (en) 2019-03-13
RU2738837C2 (ru) 2020-12-17
KR20190025545A (ko) 2019-03-11
JP6927548B2 (ja) 2021-09-01
US10835535B2 (en) 2020-11-17
WO2017193872A1 (en) 2017-11-16
KR102374033B1 (ko) 2022-03-14
TW201805290A (zh) 2018-02-16
AU2017262155A1 (en) 2018-12-06
EP3452484B1 (en) 2023-07-05
CN109153686A (zh) 2019-01-04
JP2019516790A (ja) 2019-06-20
CA3023460A1 (en) 2017-11-16
US20190209566A1 (en) 2019-07-11
CN109153686B (zh) 2021-04-30
TWI752026B (zh) 2022-01-11
ES2954148T3 (es) 2023-11-20
ZA201808238B (en) 2022-10-26
BR112018072699A2 (pt) 2019-02-19
AU2017262155B2 (en) 2021-03-11
DK3452484T3 (da) 2023-09-25
RU2018143284A (ru) 2020-06-08
RU2018143284A3 (es) 2020-07-31
EP3452484A4 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
PH12020550622A1 (en) Kras g12c inhibitors
MX2022004304A (es) Agentes inductores de apoptosis.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
PH12018500907A1 (en) Inhibitors of ret
MX2019001125A (es) Inhibidores de cinasa macrociclica.
MX2018013983A (es) Inhibidores g12c de kras.
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
MY191581A (en) Anti-pd-1 antibodies
MX2020014245A (es) Inhibidores de quinasas dependientes de ciclinas.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
PH12017500732A1 (en) Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
SG10201902326XA (en) Mk2 inhibitors and uses thereof
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
MX2020010116A (es) Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).
MX2019004690A (es) Constructos de anticuerpos.
IL264593A (en) Medicinal preparations containing akt protein kinase inhibitors
MX2020000135A (es) Nuevos compuestos de quinolinona.
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.